HALMAN ALDUBI PROVIDENT AND PENSION FUNDS LTD. v. TEVA PHARMACEUTICAL INDUSTRIES LIMITED

CourtDistrict Court, E.D. Pennsylvania
DecidedJanuary 30, 2023
Docket2:20-cv-04660
StatusUnknown

This text of HALMAN ALDUBI PROVIDENT AND PENSION FUNDS LTD. v. TEVA PHARMACEUTICAL INDUSTRIES LIMITED (HALMAN ALDUBI PROVIDENT AND PENSION FUNDS LTD. v. TEVA PHARMACEUTICAL INDUSTRIES LIMITED) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
HALMAN ALDUBI PROVIDENT AND PENSION FUNDS LTD. v. TEVA PHARMACEUTICAL INDUSTRIES LIMITED, (E.D. Pa. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

HALMAN ALDUBI PROVIDENT AND CIVIL ACTION PENSION FUNDS LTD., Plaintiff, NO. 20-4660-KSM v.

TEVA PHARMACEUTICALS INDUSTRIES LIMITED, et al., Defendants.

MEMORANDUM MARSTON, J. January 30, 2023 Presently before the Court is Lead Plaintiff Gerald Forsythe’s “Motion for Leave to File Documents Under Seal.” (Doc. No. 97.) Defendants Teva Pharmaceutical Industries Limited, Erez Vigodman, Eyal Desheh, Robert Koremans, Michael Derkacz, Kare Schultz, Michael McClellan, and Brendan O’Grady (collectively, “Defendants” or “Teva”) report that they “do not take a position on Plaintiff’s confidentiality designations, nor on the propriety of any redactions or sealing.” (Doc. No. 96.) Because we write for the benefit of the parties, who are familiar with the documents and issues before us, the Court includes only a brief recitation of the facts. I. BACKGROUND Lead Plaintiff Gerald Forsythe brings this action on behalf of individuals who purchased or otherwise acquired Teva securities between October 29, 2015, and August 18, 2020. (Doc. No. 1 at 2.) Plaintiff alleges that during this time, Defendants made materially false and misleading statements regarding the commercial success and profitability of one of Teva’s drug products, Copaxone. (Id. at 3.) As a result of Defendants’ wrongful acts and omissions, Plaintiff claims that he and other putative class members suffered a decline in the market value of their Teva securities. (Id. at 4.) Accordingly, Plaintiff seeks relief for damages caused by Defendants’ alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. (Id. at 2.) On September 13, 2022, Plaintiff filed a “Motion to Certify the Class, Appoint Class

Representative, and Appoint Class Counsel” (Doc. No. 90), seeking to certify a class consisting of those who purchased or otherwise acquired Teva securities during the class period and suffered damages from Teva’s alleged securities fraud scheme. One month later, on October 12, 2022, the Court approved the parties’ joint Confidentiality Stipulation and Proposed Protective Order, which protects documents produced during class certification discovery that may include: “(1) financial and/or investment account statements of Plaintiff; (2) individualized personal information (e.g., social security numbers and non-public residential addresses); (3) personally identifying information of non-parties; (4) medical records and medical information; and (5) confidential and/or competitively sensitive business records of Defendants.” (Doc. No. 92 at 2.)

On December 20, 2022, Defendants filed an opposition to Plaintiff’s motion to certify the class. (Doc. No. 95.) On the same day, Defendants also filed a motion for leave to file portions of their opposition memorandum and certain exhibits under seal, in accordance with the parties’ protective order. (Doc. No. 94.) On December 22, 2022, the Court denied Defendants’ motion for leave without prejudice because Defendants failed to demonstrate that a sealing order was warranted under the standard set out by the Third Circuit in In re Avandia Mktg., Sales Practices & Prods. Liab. Litig., 924 F.3d 662 (3d Cir. 2019). (Doc. No. 98.) The Court instructed Defendants to file a renewed motion to seal that addressed this standard by January 4, 2023. (Id.) Defendants informed the Court on January 3, 2023, that they did not intend to renew their motion to seal. (See Doc. No. 96 (“The information Defendants proposed to place under seal was designated confidential by Plaintiff. Accordingly, Defendants do not intend to file a renewed motion to seal.”).) Instead, Plaintiff would “move to seal some or all of the information

referenced in Defendants’ initial motion [to seal].” (Id.) On January 4, 2023, Plaintiff filed this motion, seeking to redact portions of Defendants’ Exhibits 9, 10, and 12.1 (Doc. No. 97.) Specifically, Plaintiff contends that Exhibits 9, 10, and 12 contain “highly personal financial information, including personal information wholly irrelevant to Defendants’ Class Certification Opposition….” (Doc. No. 97-1 at 5.) II. LEGAL STANDARD Although the Court previously approved a protective order in this case, a more rigorous standard applies when a party seeks to seal judicial documents than applies to protective orders shielding discovery materials. See In re Avandia, 924 F.3d at 672 (“A ‘judicial record’ is a document that has been filed with the court or otherwise somehow incorporated or integrated

into a district court’s adjudicatory proceedings.”) (quotation marks omitted). Once a discovery document becomes a judicial record, the common law presumption of the right of public access attaches. See Leucadia, Inc. v. Applied Extrusion Tech., Inc., 998 F.2d 157, 164 (3d Cir. 1993) (“We believe that our earlier decisions and those in other courts lead ineluctably to the conclusion that there is a presumptive right of public access to pretrial motions of a nondiscovery

1 Plaintiff clarifies that he does not oppose the public filing of Exhibits 1 and 13, which were included in Defendants’ initial motion to seal. (Doc. No. 97-1 at n.2.) Defendants have not renewed their arguments as to the confidentiality of these Exhibits. As of this date, Exhibit 1 and Exhibit 13 have not been made part of the judicial record; Defendants filed those exhibits with the following placeholder: “Exhibit being filed under seal pursuant to Confidentiality Stipulation and Protective Order.” (Doc. Nos. 95-2, 95-14.) Defendants are directed to file an amended opposition brief attaching Exhibits 1 and 13 in their unredacted and unsealed format. nature, whether preliminary or dispositive, and the material filed in connection therewith.”). Because Exhibits 9, 10, and 12 are filed as part of Defendants’ opposition materials, they are considered “judicial records” to which the common law right of access attaches. The right of access is not absolute, however, and may be rebutted by a showing that an

“interest in secrecy outweighs the presumption.” In re Avandia, 924 F.3d at 672. To meet this burden, the party requesting the sealing order must demonstrate that the “material is the kind of information that courts will protect, and that disclosure will work a clearly defined and serious injury to the party seeking closure.” Id. (quotation marks omitted). In addition to the common law right of access, which attaches to all judicial records, the public also has a First Amendment right of access in civil trials, which attaches to certain judicial documents. Id. at 673. The First Amendment right of access presents an even higher burden than the common law right of access, and the party requesting that trial documents be sealed must overcome strict scrutiny. Id. Specifically, the party must demonstrate “an overriding interest in excluding the public based on findings that closure is essential to preserve higher

values and is narrowly tailored to serve that interest.” Id. Under either the common law or First Amendment standard, when a court analyzes a request for a sealing order, it must do so on a document-by-document basis, and the proponent of the sealing order must articulate with specificity the injury that would result if the document or parts of it were made public. Id. Merely reciting the factors from Pansy v. Borough of Stroudsburg, 23 F.3d 772 (3d Cir 1994) in seeking a sealing order is insufficient.2 See In re

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
HALMAN ALDUBI PROVIDENT AND PENSION FUNDS LTD. v. TEVA PHARMACEUTICAL INDUSTRIES LIMITED, Counsel Stack Legal Research, https://law.counselstack.com/opinion/halman-aldubi-provident-and-pension-funds-ltd-v-teva-pharmaceutical-paed-2023.